Training Need: Curriculum Development/Facilitation

You have a need to pull together a bunch of scattered training materials/workshops into a comprehensive curriculum. Maybe you also need a vendor/partner who can not only head up design and development, but can also take the lead on organization and faciltation (locally or globally). We can help. Impactiviti’s Preferred Partner network includes some top-notch [...]

Read Full Post »

Today’s Top Three in Pharma 013009

The cuts continue – this time it’s AstraZeneca. U.K.-based drugmaker AstraZeneca PLC (AZN) Thursday forecast flat 2009 sales and unveiled plans to cut a further 7,400 jobs worldwide by 2013, while posting a 1.4% decline in fourth-quarter net profit. Roche goes hostile in bid for Genentech. Roche cut the price of its bid for outstanding [...]

Read Full Post »

Today’s Top Three in Pharma 012909

Sepracor cutting 20% of its workforce. Ouch. Sepracor Inc, maker of the Lunesta sleep drug, said on Wednesday it would cut about 20 percent of its workforce, or 530 jobs, in an effort to save some $210 million in expenses, and its shares jumped 17 percent. The company said most of the cuts would come [...]

Read Full Post »

Today’s Top Three in Pharma 012809

Astellas makes a big to acquire CV Therapeutics. Japan’s Astellas Pharma is offering a billion dollars in cash for CV Therapeutics. The bid comes in at $16 a share, a whopping 41 percent premium over yesterday’s close. Abilify as an add-on therapy for depression – not everyone is convinced. Watson‘s topical Overactive Bladder gel (Gelnique) [...]

Read Full Post »

Today’s Top Three in Pharma 012709

Enormous Bextra charge taken by Pfizer – If you’re going to take a $2.3 billion earnings hit over government investigations, you might as well announce it the same day everybody’s more interested in your $68 billion deal. Amid the hullaballoo over Pfizer’s bid for Wyeth today, Pfizer announced its fourth-quarter earnings, which fell to $266 [...]

Read Full Post »

Today’s Top Three in Pharma 012609

Of course, the huge news this Monday morning…Pfizer buying Wyeth. This will dominate the headlines for days. Before the deal was announced, Jim Edwards did some analysis on potential downsides – interesting stuff. This also means that the Wyeth-Crucell discussions are scuttled. And who else may be making deals in the days ahead? My take, [...]

Read Full Post »

After Hours 012309

Searching for on-line images by color. Endless fun and fascination. One Year in 40 Seconds. One of the better time-lapse photography experiments I’ve seen. Social Networking Dos and Don’ts. Helpful tips for those who communicate on-line.

Read Full Post »

Today’s Top Three in Pharma 012309

BREAKING RUMOR – Pfizer in talks to acquire Wyeth. Will contract sales reps rule in the future? Revenues are now following a “cyclical pattern surrounding patent expirations,” In Vivo quotes Ryan as saying. So pharma companies need to have sales forces that can follow the same kind of cycle, shrinking as revenues sink, she suggests. [...]

Read Full Post »

Training Need: Specialty Workshops

You’re in a small/mid-sized pharma or biotech company with specialty products. Or a big pharma with specialty field forces. Where do you find workshops (for ongoing training, POAs, etc.) that are tailored to your needs? We can help. Impactiviti’s preferred partner network can provide workshops for topics such as: Business Acumen and Analysis for Specialty [...]

Read Full Post »

Today’s Top Three in Pharma 012209

Social Networking in our industry*. PharmaExec looks at the use of social networking platforms among physicians. And, an abstract of Manhattan Research‘s findings (scroll past TOC to read excerpt). A new kind of social network has been gaining traction among doctors – namely, physician-only communities where doctors can exchange ideas, opinions, and information about treatments [...]

Read Full Post »